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Unresectable gastroesophageal junction (GEJ) cancers have a poor prognosis and limited treatment options. We report the
case of a patient with a Siewert class III gastroesophageal junction squamous carcinoma with metastatic spread into the
liver who had an exceptional response to a combination therapy of nivolumab and ipilimumab despite being programmed
death-ligand 1 (PD-L1) negative, microsatellite stable (MSS), and having a low tumor mutational burden. He initially
experienced disease progression on the chemotherapy regimens modiﬁed DCF and FOLFIRI resulting in limited functional
status, esophageal stent placement, and feeding tube placement. After about 6 months on nivolumab and ipilimumab, he
had near-complete disease resolution. He was able to return to his baseline functional status, as well as have the
esophageal stent and feeding tube removed. Our case contributes to the value of exploring immunotherapy as an option
for a variety of hard to treat cancers.
1. Introduction
Immunotherapy with checkpoint inhibitors continues to
become a more common treatment option for a variety
of cancers. Many studies have established the beneﬁt of
programmed cell death protein 1 (PD-1) and cytotoxic T-
lymphocyte antigen-4 (CTLA-4) checkpoint inhibitors in
the treatment of melanoma, renal cell carcinoma, and
non-small cell lung cancer [1–3]. In most other cancers,
the beneﬁts of immunotherapy have been limited. Reports
of excellent immunotherapy responses in squamous cell can-
cers of the head and neck and primary squamous cell cancers
of the skin have been accumulating [4]. Squamous histology
is not a common feature in primary gastric cancer represent-
ing 0.04% to 0.07% of all cases [5]. Despite FDA immuno-
therapy approvals for GEJ cancer that overexpress PD-L1
or are found to be microsatellite instable, the majority of
GEJ cancers do not ﬁt these criteria [6]. The CheckMate-
032 study showed modest results for patients with metastatic
GEJ cancer treated with nivolumab or a combination of nivo-
lumab and ipilimumab. Response rates were numerically
lower in immunologically cold tumors [7]. GEJ cancers are
often diagnosed with regional lymph node involvement or
metastatic disease making platinum and ﬂuoropyrimidine-
based systemic chemotherapy the initial treatment, even if
the patient is going to undergo a surgical resection [8]. Tras-
tuzumab is another agent often considered in metastatic GEJ
cancers as 6.0% to 29.5% may overexpress human epidermal
growth factor receptor 2 (HER2) [9]. Here, we present a case
of a patient with a GEJ squamous carcinoma who experi-
enced disease progression despite two diﬀerent chemother-
apy regimens, who then had an exceptional response to
combination therapy of nivolumab and ipilimumab.
2. Case Presentation
The patient is a 50-year-old male who presented to the oﬃce
in April 2017 for a 50-pound weight loss over the past year,
fatigue, and diﬃculty swallowing solid foods. After initial
imaging, an endoscopic ultrasound (EUS) showed a Siewert
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class III gastroesophageal junction mass extending from
the top of the gastric folds to the body of the stomach
(Figure 1), multiple bulky nearby lymph nodes with the larg-
est lymph node being 5 cm, and a T3N3 staging by the EUS
criteria. Biopsy of the gastric mass revealed it was a high-
grade carcinoma with glandular, neuroendocrine, and squa-
mous diﬀerentiation. The tumor cells stained positive for
the tumor markers pancytokeratin AE1/AE3, synaptophysin,
p40, and CDX2 and did not overexpress HER2. An MRI in
early May showed a 9mm liver metastasis. He began
treatment in May with modiﬁed DCF (docetaxel 40mg/m2,
cisplatin 40mg/m2, and 5-ﬂuorouracil 2000mg/m2). Foun-
dation One genomic alterations demonstrated the gene
locations SMARCA4 P319fs∗7 and TP53 splice site 375
+1G>A which were not actionable. Molecular markers for
PD-L1 and microsatellite instability were negative, and the
tumor mutation burden was low (4 mutations/megabase).
In August, after he completed 6 cycles of modiﬁed DCF,
chemotherapy was switched to FOLFIRI (leucovorin calcium,
5-ﬂuorouracil, and irinotecan hydrochloride) due tomild dis-
ease progression on CT imaging and extreme fatigue from the
modiﬁed DCF. Despite showing some initial response to the
FOLFIRI on imaging, his FOLFIRI was held after 6 cycles
in November due to severe nausea/vomiting and dehydra-
tion. He underwent multiple esophagogastroduodenoscopies
(EGDs) later in November resulting in balloon dilatation and
liquid nitrogen cryotherapy for a near-complete GEJ obstruc-
tion and eventually had an esophageal stent placed. He also
had a percutaneous endoscopic gastrostomy (PEG) tube
placed around this time since he could not tolerate eating
by mouth. CT imaging in December showed worsening
metastatic disease in the liver.
Based on the early data of CheckMate-032, the unique
squamous histology of this patient’s cancer, and the recent
successes of PD-1 inhibition in other squamous carcinomas
of the skin and head and neck, his treatment was switched
to the oﬀ-label use of ipilimumab and nivolumab in Decem-
ber 2017. Due to his weakened condition and the known high
concern for immune-related adverse events with the dual
checkpoint blockade, the ﬁrst 2 cycles were given with a
reduced dose of ipilimumab at 1mg/kg and nivolumab at
3mg/kg. When he demonstrated good tolerance, this was
followed by 4 cycles of ipilimumab at 3mg/kg and nivolumab
at 1mg/kg. Also, at this time, he received 14 radiation treat-
ments to the GEJ for obstruction. Over the next several
months, he began to feel better, and his esophageal stent
(a) (b)
Figure 1: (a) Top of mass visualized on initial esophagogastroduodenoscopy. (b) Ulcerated portion of mass visualized on initial
esophagogastroduodenoscopy.
(a) (b)
Figure 2: (a) Baseline axial fused PET/CT fromMay 2017 showing increased FDG uptake. (b) Axial fused PET/CT fromMarch 2019 showing
resolution of increased FDG uptake.
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was removed at the end of March, as his scans showed
improvement of the GEJ mass and metastatic hepatic lesions.
His treatment was modiﬁed to monthly maintenance of nivo-
lumab at a ﬁxed dose of 480mg starting in May 2018, and by
June, he could eat without vomiting and was able to return to
work full time. His PEG tube was removed in July. Later that
month, a PET scan showed resolution of ﬂuorodeoxyglucose
(FDG) avidity in the GEJ, abdominal lymph nodes, and near
total resolution in the hepatic metastases. He showed incred-
ible improvement on ipilimumab and nivolumab with the
main adverse eﬀect being mild thyroiditis. His CT scan in
November 2018 shows resolution of all visible disease, and
a PET/CT scan in March 2019 was negative for the uptake
of FDG isotope at all sites of disease (Figure 2). He will
remain on monthly maintenance with nivolumab 480mg
until the end of the 2019.
3. Discussion
The patient’s clinical course signiﬁcantly changed from
decreasing functional status and worsening tumor burden
to near-complete resolution following treatment with nivo-
lumab and ipilimumab. Since he also received radiation
therapy during the initial part of the immunotherapy treat-
ment, it is diﬃcult to deﬁnitively say what role the radia-
tion played in terms of the abscopal eﬀect. The radiation
likely contributed to the improvement of the patient’s GEJ
mass, but the continued improvement of nonradiated met-
astatic lesions in the months following the conclusion of
the radiation therapy points to the substantial role of nivo-
lumab and ipilimumab.
Interestingly, the patient’s tumor was PD-L1 negative,
had a low tumor mutational burden, and was MSS giving it
features suggestive that cancer would be less likely to respond
to immunotherapy. Immunotherapy biomarkers is an area
where there is still a signiﬁcant room for improvement to
determine which patients will beneﬁt from therapy. In this
case, the rare squamous histology may have played a role
given the recent success of immunotherapy in squamous cell
cancers of the head and neck. It is possible that squamous
cells have a feature that makes them more susceptible to
immunotherapy. Alternatively, a PD-L1-positive status has
some inherent variability. Some tumors may constitutively
express PD-L1 while others only express it when T-cells
inﬁltrate the tumor [10]. Thus, it is possible that the lack
of T-cell inﬁltrate during sampling resulted in a false-
negative PD-L1 status for our patient. While the exact mech-
anism of PD-L1 negative tumor response to nivolumab may
be unknown, our patient who switched to only nivolumab
after 6 cycles of combination immunotherapy continued to
show improvement.
In conclusion, our case is an example of an exceptional
response to immunotherapy in a patient who was running
out of options after failing two chemotherapy regimens. He
went from gastric tube feeds and an esophageal stent to keep
his esophagus from collapsing to returning to his usual activ-
ities of daily living. His GEJ cancer responded spectacularly
to immunotherapy despite having biomarkers suggestive of
a poor response. A possible avenue for a future work would
be to further investigate whether squamous histology is a
feature in gastric cancer that indicates better response to
immunotherapy. Our case contributes to the value of explor-
ing immunotherapy as an option for a variety of hard to
treat cancers.
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